BMRA
Biomerica, Inc. · Healthcare
2.17
0.00%(+0.00)
Prev. Close2.23
2.76%(+0.06)
Pre-marketLast Updated: — ET
52W L: $1.8752W H: $4.88
$2.17
CHG+0.35 (+19.23%)
H$2.48
L$1.82
VOL372K
BMRA (1h)
Biomerica, Inc. · Healthcare
Biomerica (NASDAQ: BMRA - Get Free Report) is anticipated to post its results after the market closes on Monday, April 13th. Analysts expect Biomerica to post earnings of ($1.20) per share and revenue of $3.6290 million for the quarter. Biomerica (NASDAQ: BMRA - Get Free Report) last released its quarterly earnings results on Wednesday, January 14th. The
IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first commercial order for Hp Detect™, its Helicobacter pylori (H. pylori) diagnostic stool antigen test, from one of the largest clinical laboratory chains operating across Europe. The initial order is for the United Kingdom market, where Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026.
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized. Disease Burden: The WHO designates H.
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial. CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.67 and traded as low as $2.06. Biomerica shares last traded at $2.10, with a volume of 12,929 shares changing hands. Biomerica Stock Down 3.2% The company
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is working with a major healthcare products distributor in Vietnam who will manage the sales and distribution of the product through pharmacies, hospitals, physician's offices, and direct online sales channels.
Chin Eric
director
22,500 SH @ $0.00
2025-12-12
Lu Gary
officer: Chief Financial Officer
40,000 SH @ $0.00
2025-12-12
Irani Zackary S.
director, officer: Chief Executive Officer
52,500 SH @ $0.00
2025-12-12
BARBIERI ALLEN
director, officer: Executive Vice-Chairman
30,000 SH @ $0.00
2025-12-12
MOATAZEDI DAVID
director
20,000 SH @ $0.00
2025-12-12
Gary M. Huff
director
20,000 SH @ $0.00
2025-12-12
Chin Eric
director
0 SH @ $0.00
2025-06-04
Emerson Jane
director
85,000 SH @ $0.31
2024-12-13